Related Experiment Videos
Novel scaled average bioequivalence limits based on GMR and variability considerations
Vangelis Karalis1, Mira Symillides, Panos Macheras
1Laboratory of Biopharmaceutics-Pharmacokinetics, School of Pharmacy, University of Athens, Athens, Greece.
Pharmaceutical Research
|November 24, 2004
Summary
Novel bioequivalence (BE) methods, BELscG1 and BELscG2, effectively assess drug product similarity by incorporating intrasubject variability and geometric mean ratio (GMR). These approaches offer high statistical power across various conditions, improving the evaluation of average BE.
Area of Science:
- Pharmacokinetics and Pharmaceutical Sciences
- Biostatistics
- Drug Regulatory Science
Background:
- Bioequivalence (BE) studies are crucial for demonstrating therapeutic equivalence between generic and reference drug products.
- Current BE assessment methods, particularly scaled approaches, aim to balance statistical power with the acceptance of genuine product differences.
- Intrasubject variability and the geometric mean ratio (GMR) are key parameters influencing the sensitivity and reliability of BE assessments.
Purpose of the Study:
- To develop novel bioequivalence (BE) limit approaches that integrate intrasubject variability and geometric mean ratio (GMR).
- To evaluate the performance of these new scaled BE procedures against existing methods and unscaled average BE.
- To provide a more nuanced assessment of average BE by considering formulation variability and similarity.
Main Methods:
- Development of GMR-dependent bioequivalence (BE) limits, BELscG1 and BELscG2, incorporating intrasubject variance (s).
- Simulation of two-period crossover BE studies with varying subject numbers (12, 24, 36) and coefficients of variation (CV: 10% to 40%).
- Comparison of acceptance rates and statistical power of novel scaled procedures against classic unscaled average BE and other scaled methods.
Main Results:
- Two novel GMR-dependent BE limits (BELscG1, BELscG2) were derived, with limits narrowing as GMR deviates from unity and widening with increased variability.
- The proposed methods demonstrated high statistical power, particularly at low CV values and high levels of variability.
- BELscG1 and BELscG2 showed superior performance, yielding the lowest acceptance rates at GMR=1.25, especially with larger study populations.
Conclusions:
- Geometric mean ratio (GMR) and coefficient of variation (CV) estimates from BE studies can effectively inform average BE assessment using GMR vs. CV plots.
- The novel BELscG1 and BELscG2 approaches are robust and highly effective across all investigated levels of variability.
- These advanced methods enhance the precision and reliability of bioequivalence evaluations for drug products.